Cancer Research and Statistic Foundation

What Cancer Research and Statistic Foundation does

Cancer Research and Statistic Foundation (CRSF) is a Mumbai-based nonprofit trust founded in 1990 that operates across the Indian oncology ecosystem as a research coordinator, professional educator, and patient support provider. Its core offerings include the peer-reviewed quarterly open-access journal "Cancer Research, Statistics, and Treatment" (CRST), a free Next-Generation Sequencing biomarker testing program (TARGT First / TRF) delivered via lab partner 4baseCare and the LuNGS Alliance, a tiered professional membership program (Life Rs. 2,000, Annual Rs. 1,000, Student Rs. 500, Overseas USD 30), and an annual conference and webinar portfolio spanning 9th-edition flagship lung cancer events plus specialty summits across multiple cities. The foundation also runs Phase 2 and Phase 3 clinical trials in head and neck cancer, glioma, oral cavity cancer, breast cancer, and scalp cooling, with published results in ASCO journals.

CRSF monetizes primarily through pharmaceutical industry sponsorship (AstraZeneca, Roche, Pfizer, Bristol Myers Squibb, Eli Lilly, Johnson & Johnson) and institutional support from Tata Memorial Hospitals, supplemented by nominal membership fees and event-related revenue. Underlying technology is light: the foundation does not disclose proprietary platforms, relying instead on partner labs (4baseCare) for genomics and StatsCure for data analytics. Strategic distribution is achieved through a 13-member Scientific Committee, a Scientific Committee-led governance structure that grants members protocol-design and voting rights, and a Scientific Committee-anchored network of medical oncologists, associate members, and student members across India. Patient-facing services include financial assistance, medicine donations, fertility preservation support, and accommodation coordination.

The customer base is bifurcated: medical oncologists (primary segment, with protocol participation and voting rights), associate healthcare professionals and postgraduate students (secondary), and cancer patients (tertiary, served via free testing and support programs). Geographic operations are concentrated in India, with global engagement through the open-access journal and overseas membership.

Name

Cancer Research and Statistic Foundation

Legal name

Cancer Research and Statistic Foundation Trust

Website

https://crsf.in

Company type

Private

Founded year

1990

Operating status

Operating

Headcount range

51–100 employees

Short description

Cancer Research and Statistic Foundation is a 35-year-old Mumbai-based nonprofit trust that advances oncology in India through the peer-reviewed CRST journal, free NGS biomarker testing, Phase 2/3 clinical trials, and a national conference and membership network serving medical oncologists, students, and cancer patients.

Ownership category

akta.pro rank

Product category

Oncology Research & Education

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro primary industry

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)

akta.pro secondary industries

Clinical CROs (Phase I–IV) (HLAGAAAA), Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI)

Keywords

• Cancer research
• Clinical oncology
• Medical education
• Genomic testing
• Patient support

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Membership Fees: CRSF generates revenue through membership fees with tiered pricing: Life Membership at Rs. 2,000, Annual Membership at Rs. 1,000, Student Annual Membership at Rs. 500, and Overseas Membership at USD 30. These fees provide access to CRSF network resources, patient education materials, and voting rights.
2. Pharmaceutical Industry Support: The foundation receives support from pharmaceutical companies including AstraZeneca, Roche, Pfizer, Bristol Myers Squibb, Eli Lilly, and Johnson & Johnson for their testing programs and educational activities. This appears to be in the form of program sponsorship rather than direct revenue.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

CRSF is an Indian nonprofit trust that advances cancer research, education, and patient care through a peer-reviewed oncology journal (CRST), free NGS biomarker testing for cancer patients, tiered professional membership, and a large portfolio of oncology conferences, masterclasses, and webinars. It also coordinates Phase 2/3 clinical trials and provides financial, medical, and fertility-preservation support to cancer patients.

Product overview

CRSF operates as a cancer research foundation offering a unified portfolio of products and services centered on oncology research, education, and patient care. The core offerings include: the CRST (Cancer Research, Statistics, and Treatment) Journal, a peer-reviewed academic publication; the Free NGS Biomarker Test program (TRF) providing next-generation sequencing testing through partnerships with LuNGS Alliance and 4baseCare; professional membership programs for oncology professionals; educational events and conferences; clinical research studies; and patient and healthcare provider support services. The foundation serves the oncology community through awareness creation, research promotion, and direct patient support.

Differentiator

Problem solved

Functional benefit

Brands

• CRST Journal: Cancer Research, Statistics, and Treatment - peer-reviewed quarterly open-access journal covering cancer research, statistics, and treatment.

Products and services

• Cancer Research, Statistics, and Treatment (CRST) Journal Peer-reviewed, quarterly, open-access journal publishing technical and clinical studies on health, ethical and social issues in cancer research, statistics, and treatment. Serves clinical oncologists, researchers, and translational scientists globally who submit or read research findings, with preference for articles carrying clinical implications.
• Free NGS Biomarker Testing Program (TRF / TARGT First) Free TARGT First NGS biomarker testing offered to cancer patients (primarily lung cancer) through a Test Requisition Form (TRF). Samples are collected and processed by laboratory partner 4baseCare, with results supporting targeted therapy selection. The service is funded by pharmaceutical sponsors AstraZeneca, Roche, Pfizer, Bristol Myers Squibb, Eli Lilly, Johnson & Johnson, and supported by Tata Memorial Hospitals.
• CRSF Professional Membership Online-registered professional membership for oncology professionals and postgraduate students. Includes Life, Annual, Student Annual, and Overseas tiers, granting access to CRSF network resources, patient education materials, voting rights, and eligibility for protocol participation and committee positions.
• Oncology Education Events and Conferences In-person and hybrid continuing medical education events for oncologists and oncology professionals. Portfolio includes the Masterclass in Lung Cancer series, Year End Reviews, Knowledge Series for Genitourinary Cancers, multidisciplinary oncology summits, and ASCO/ESMO/WCLC update webinars. Delivered across multiple Indian cities.
• Patient Support Services Direct support services for cancer patients covering financial assistance for treatment costs, accommodation during treatment, donation of medicines and supportive care drugs, fertility preservation, and assistance with job placement and social reintegration. Targeted at individual cancer patients and their families in India.
• Doctor and Hospital Support Services Capacity-building and operational support provided to oncologists and hospitals, including expertise for launching advanced treatment techniques, development of cancer wings, supply of essential amenities, educational travel and conference support, blood bank camp assistance, and educational or research activity support.

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

13 partnerships are on record, tiered core and major.

• LuNGS AlliancecoreStrategic or Co-development PartnerLuNGS Alliance is a supporting partner in CRSF's free NGS biomarker testing program (TARGT First). The collaboration enables comprehensive genomic testing for lung cancer patients to identify mutations and guide treatment decisions.
• 4baseCarecoreTechnology or Integration4baseCare serves as the laboratory partner for CRSF's free NGS biomarker testing program. They perform the actual laboratory testing for genomic mutations from collected patient samples.
• StatsCuremajorTechnology or IntegrationStatsCure is listed as CRSF's data partner, providing advanced analytics solutions for healthcare providers to make informed decisions, enhance patient outcomes, and streamline operations.
• AstraZenecamajorOthersAstraZeneca is one of the pharmaceutical industry leaders supporting CRSF's free NGS biomarker testing program (TARGT First) for cancer patients.
• RochemajorOthersRoche is listed as a supporting pharmaceutical partner for CRSF's free biomarker testing program, contributing to patient access to genomic testing.
• PfizermajorOthersPfizer supports CRSF's free NGS testing initiative as part of pharmaceutical industry partnership for improving cancer patient access to biomarker testing.
• Bristol Myers SquibbmajorOthersBristol Myers Squibb (BMS) is a pharmaceutical supporter of CRSF's free biomarker testing program, enabling cancer patients to access genomic testing.
• Eli LillymajorOthersEli Lilly supports CRSF's patient testing program as part of their commitment to improving cancer care through biomarker testing access.
• Johnson & JohnsonmajorOthersJohnson & Johnson is listed among the pharmaceutical industry leaders supporting CRSF's free NGS biomarker testing program.
• Tata Memorial HospitalsmajorStrategic or Co-development PartnerTata Memorial Hospitals is supported by CRSF as part of their ecosystem of leading industry names, contributing to cancer research and treatment initiatives.
• Sunrise Oncology CentrecoreStrategic or Co-development PartnerSunrise Oncology Centre is a key organizational partner, hosting major CRSF events including the 1st Sunrise Oncology Cancer Summit and Masterclasses in Lung Cancer.
• SunAct Cancer InstitutecoreStrategic or Co-development PartnerSunAct Cancer Institute is a supported organizational partner and co-organizer of major CRSF events including the 9th Annual Year End Review in Lung Cancer.
• Institute of Pulmonology Medical Research & DevelopmentmajorStrategic or Co-development PartnerThis institute supports CRSF's lung cancer educational programs and research activities as part of the organizational ecosystem.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Regional players

• Tata Memorial Centre: Tata Memorial Centre is India's premier cancer hospital and research institution and an established CRSF ecosystem partner. While it is primarily a hospital rather than a foundation, its research, training, and protocol-development activities overlap directly with CRSF's clinical-research and education mission in India.
• National Cancer Grid (India): National Cancer Grid is an India-centric network of cancer centers coordinated by Tata Memorial Centre for collaborative research, education, and guideline development. It is comparable to CRSF in promoting oncology research and education within India, and overlaps on hospital-network and protocol-development activities.

Direct peers

• Indian Cooperative Oncology Network (ICON): ICON is an Indian oncology cooperative that designs and coordinates multi-center clinical trials and treatment protocols across member hospitals. It directly overlaps CRSF's protocol-design, patient-registration, and cooperative-trial activities, making it the closest functional peer for CRSF's clinical-research operations.
• Indian Society of Medical & Paediatric Oncology (ISMPO): ISMPO is an Indian professional society for medical and pediatric oncologists, running conferences, CME programs, and guidelines work. It is the most directly comparable Indian oncology society to CRSF, competing for the same members, conference attendees, and pharma educational sponsorship.

Broad incumbents

• Cancer Research UK: Cancer Research UK is a major international cancer research charity funding research, running public-awareness campaigns, and supporting patients. It is comparable to CRSF as a nonprofit cancer foundation with research, education, and patient-support mandates, but operates at substantially larger scale and global brand recognition.
• European Society for Medical Oncology (ESMO): ESMO is a Europe-based oncology professional society offering membership, congresses (ESMO Congress), and journals (Annals of Oncology). It is comparable to CRSF in mission and structure (membership body + journal + conferences + educational programs), serving as a regional parallel that competes for global pharma educational sponsorship.
• American Society of Clinical Oncology (ASCO): ASCO is the largest global oncology professional society, publishing the Journal of Clinical Oncology and running major conferences (ASCO Annual Meeting). Like CRSF, it combines professional membership, peer-reviewed publishing, and clinical education, but operates at a much larger global scale and serves as the benchmark CRSF aspires to in the Indian market.
• American Association for Cancer Research (AACR): AACR is a global cancer research organization that publishes major journals (Cancer Research, Clinical Cancer Research) and runs large annual meetings. It is comparable to CRSF on the research-publication and conference-organization axes, and represents the upper bound of what CRSF's CRST journal and masterclass model could grow into.

Others

• 4baseCare: 4baseCare is an India-based genomics and precision oncology company that operates NGS lab services. It is CRSF's lab partner for the TRF program and adjacent as a precision-oncology player serving the same Indian oncologist and patient base, though it operates commercially while CRSF is nonprofit.
• LuNGS Alliance: LuNGS Alliance is the supporting partner for CRSF's TARGT First NGS biomarker testing program for lung cancer patients. It is an ecosystem partner rather than a direct competitor, but both organizations are aligned around expanding genomic testing access for Indian oncology patients.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/cancercrsf
• YouTubeyoutube.com/@crsfindia
• Facebookfacebook.com/CRSFINDiA
• LinkedInlinkedin.com/company/crsf

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cancer Research and Statistic Foundation